Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inosine 5'-monophosphate (IMP) is a purine nucleotide composed of the base hypoxanthine attached to a ribose sugar and one phosphate group esterified at the 5' position. It is an important intermediate in purine metabolism and serves as a precursor for the synthesis of adenosine monophosphate (AMP) and guanosine monophosphate (GMP). IMP acts as a substrate for enzymes such as inosine-5'-monophosphate dehydrogenase (IMPDH), which catalyzes its conversion to xanthosine monophosphate (XMP), a key step in guanine nucleotide biosynthesis. In research and food industries, IMP is used as an umami flavor enhancer due to its synergistic effect with glutamate[2][3][10]. It has no approved pharmaceutical indications but has been investigated experimentally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inosine 5'-monophosphate.